Li Jialin, Huang Sigen, Liu Shengyin, Liao Xinzhi, Yan Sheng, Liu Quanliang
The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Front Physiol. 2023 May 25;14:1118342. doi: 10.3389/fphys.2023.1118342. eCollection 2023.
The solute-linked carrier 26 (SLC26) protein family is comprised of multifunctional transporters of substrates that include oxalate, sulphate, and chloride. Disorders of oxalate homeostasis cause hyperoxalemia and hyperoxaluria, leading to urinary calcium oxalate precipitation and urolithogenesis. SLC26 proteins are aberrantly expressed during kidney stone formation, and consequently may present therapeutic targets. SLC26 protein inhibitors are in preclinical development. In this review, we integrate the findings of recent reports with clinical data to highlight the role of SLC26 proteins in oxalate metabolism during urolithogenesis, and discuss limitations of current studies and potential directions for future research.
溶质连接载体26(SLC26)蛋白家族由多种多功能转运蛋白组成,这些转运蛋白的底物包括草酸盐、硫酸盐和氯化物。草酸盐稳态紊乱会导致高草酸血症和高草酸尿症,进而导致草酸钙在尿液中沉淀并引发尿路结石形成。SLC26蛋白在肾结石形成过程中异常表达,因此可能成为治疗靶点。SLC26蛋白抑制剂正处于临床前开发阶段。在本综述中,我们将近期报告的研究结果与临床数据相结合,以突出SLC26蛋白在尿路结石形成过程中草酸盐代谢中的作用,并讨论当前研究的局限性以及未来研究的潜在方向。